BioOutsource Opens New Facility in Glasgow

Doubles the Company's Capacity for Biologics Contract Testing and Biosimilar Characterisation in Response to Surging Demand, and Creates 50 New Jobs

Glasgow, Scotland – BioOutsource Ltd. ("BioOutsource"), part of Sartorius Stedim Biotech Group and a global leader in biologics contract testing and biosimilar characterisation for the biopharmaceutical industry, today announced the opening of a new facility which doubles Biooutsource's capacity for future growth.

"Our opening of this new, state-of-the-art facility demonstrates our commitment to our growing list of global customers," commented BioOutsource CEO, Gerry MacKay. "Demand for our services remains high and we are doubling our capacity to make sure we are ready to support the robust pipeline of biotech and biosimilar products currently in development.

It is estimated that in opening and running the new facility, BioOutsource will create approximately 50 new jobs for scientific and technical professionals in the next six months.

Mr. MacKay continued, "This is a great opportunity for Life Science professionals to join an exciting and rapidly growing company. With the recent acquisition by Sartorius Stedim Biotech we expect to become one of the largest employers in this sector in Scotland and further investment in new services is already planned".

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.